DiscoverDermDocsIL-31 Mechanism of Action and Clinical Implications for Prurigo Nodularis
IL-31 Mechanism of Action and Clinical Implications for Prurigo Nodularis

IL-31 Mechanism of Action and Clinical Implications for Prurigo Nodularis

Update: 2024-11-26
Share

Description

This is the second episode of a two-part miniseries, "IL-31 Inhibition for Treatment of Prurigo Nodularis" series, supported by an educational grant from Galderma. Hosted by expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, this episode, "IL-31 Mechanism and Clinical Implications for PN", featuring Dr. Shawn Kwatra, discusses the following topics:

  • Mechanism of action for IL-31 inhibitor nemolizumab

  • Clinical safety and efficacy data for nemolizumab for treatment of PN

  • Strategies for prescribing IL-31 inhibitors in clinical practice

  • Pearls for patient selection and addressing treatment challenges

Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

IL-31 Mechanism of Action and Clinical Implications for Prurigo Nodularis

IL-31 Mechanism of Action and Clinical Implications for Prurigo Nodularis